Neoadjuvant Chemotherapy Response in Metaplastic Carcinoma of Triple Negative Breast Cancer
Neoadjuvant Chemotherapy Response in Metaplastic Carcinoma of Triple Negative Breast Cancer
prospective study for response of neoadjuvant chemotherapy in metaplastic carcinoma of triple
 negative breast cancer
Vimentin/Pan CK staining will be performed on tissues of patient who visited Seoul National
 University Hospital and were diagnosed with triple negative breast cancer and decided to
 perform neoadjuvant chemotherapy under clinical judgement.

 Histologically determined to be a metaplastic breast cancer or tested positive for
 vimentin/Pan CK patients decides as the metaplastic breast cancer. They evaluate the response
 rate of the neoadjuvant chemotherapy.

 Patients with vimentin/Pan CK negative are diagnosed with non-metaplastic breast cancer and
 this group also confirms the response rate of neoadjuvant chemotherapy.

 The group of metaplastic breast cancer will enroll 50 people, and the group of
 non-metaplastic breast cancer will enroll 100 people.
Inclusion Criteria:

 -  over 20 years old

 -  patients with triple negative breast cancer diagnosed Seoul National University
 Hospital

 -  patients who decided to perform neoadjuvant chemotherapy under clinical judgement

 Exclusion Criteria:

 -  not applicable